Sox2 also maintains the phenotype of breast cancer stem/progenitor cells by activating Wnt signaling, thereby rendering EsR+ breast cancer cells insensitive to tamoxifen treatment [14]. This evidence concerns the gene SOX2 and breast carcinoma.